mk-6240

Pre-diabetes

Columbia UniversityPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

45 Active assets in the Pre-diabetes cohort.

Asset / Sponsor	Phase	Rating
Metformin Yu Chen	Phase 4	A
Liraglutide Woman's	Phase 4	BBB
Exenatide RenJi Hospital	Phase 4	BBB
Semaglutide The University of Texas Health Science Center at San Antonio	Phase 4	BBB
Semaglutide Esbjerg Hospital - University Hospital of Southern Denmark	Phase 4	BBB

View all 50 →

Same molecule, other indications

mk-6240 is also rated in:

Alzheimer diseaseDormant

BB

Indicative ·

65 / 100

Down syndromeDormant

B

Indicative ·

60 / 100

cognitive disorderDormant

B

Indicative ·

59 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.